DcR1 Anticorps
(Tumor Necrosis Factor Receptor Superfamily, Member 10c (TNFRSF10C))
Choisissez l’un des 99 anticorps DcR1 de notre liste de produits basés sur 7 publications et 31 images de validation.
Découvrez des anticorps DcR1 fiables issus d’une large sélection de fabricants renommés. Notre portefeuille permet une détection précise de DcR1 dans plusieurs espèces, y compris Human, Mouse, Rat, C. elegans, et prend en charge diverses applications de recherche telles que WB, ELISA, FACS, ICC, IF.
Trouvez rapidement l’anticorps adapté grâce à nos outils de recherche, de filtrage et de comparaison. Chaque page produit fournit des données de validation détaillées, des références bibliographiques et des retours d’utilisateurs. Contrairement aux ressources dédiées uniquement à la comparaison, vous pouvez acheter directement les anticorps sur notre site. Choisissez parmi des anticorps polyclonaux, monoclonaux ou recombinants DcR1, issus de différents hôtes tels que Rabbit, Mouse, Goat. Parcourez nos produits ci-dessous et commandez directement pour soutenir vos recherches en toute confiance.
Les noms alternatifs de DcR1 sont TNFRSF10C.
| Catalog no. | Produit | Reactivité | Hôte / Clonalité | Application | Prix et délai de livraison |
|---|---|---|---|---|---|
| DcR1 anticorps (AA 51-150) (AbBy Fluor® 680) | Humain | Lapin Polyclonal |
|
426,37 €
Voir le prix
|
|
| DcR1 anticorps (AA 51-150) (AbBy Fluor® 647) | Humain | Lapin Polyclonal |
|
426,37 €
Voir le prix
|
|
| DcR1 anticorps (AA 51-150) (AbBy Fluor® 488) | Humain | Lapin Polyclonal |
|
426,37 €
Voir le prix
|
|
| DcR1 anticorps (AA 51-150) (AbBy Fluor® 555) | Humain | Lapin Polyclonal |
|
426,37 €
Voir le prix
|
|
| DcR1 anticorps (AA 51-150) (Biotin) | Humain | Lapin Polyclonal |
|
419,50 €
Voir le prix
|
|
| DcR1 anticorps (AA 51-150) (AbBy Fluor® 750) | Humain | Lapin Polyclonal |
|
426,37 €
Voir le prix
|
|
| DcR1 anticorps (AA 51-150) (Cy3) | Humain | Lapin Polyclonal |
|
437,53 €
Voir le prix
|
|
| DcR1 anticorps (AA 51-150) (AbBy Fluor® 594) | Humain | Lapin Polyclonal |
|
426,37 €
Voir le prix
|
|
| DcR1 anticorps (AA 51-150) (Cy5) | Humain | Lapin Polyclonal |
|
437,53 €
Voir le prix
|
|
| DcR1 anticorps (AA 51-150) (HRP) | Humain | Lapin Polyclonal |
|
437,53 €
Voir le prix
|
|
| DcR1 anticorps (AA 51-150) (Cy5.5) | Humain | Lapin Polyclonal |
|
437,53 €
Voir le prix
|
|
| DcR1 anticorps (AA 51-150) (FITC) | Humain | Lapin Polyclonal |
|
437,53 €
Voir le prix
|
|
| DcR1 anticorps (AA 51-150) (Cy7) | Humain | Lapin Polyclonal |
|
437,53 €
Voir le prix
|
|
| DcR1 anticorps | Humain | Souris Polyclonal |
|
602,82 €
Voir le prix
|
|
| DcR1 anticorps (2nd Extracellular Domain) | Humain, Souris, Rat | Lapin Polyclonal |
|
539,00 €
Voir le prix
|
|
| DcR1 anticorps (AA 32-244) | Humain | Lapin Polyclonal |
|
220,00 €
Voir le prix
|
|
| DcR1 anticorps | Humain, Souris, Rat | Lapin Polyclonal |
|
815,38 €
Voir le prix
|
|
| DcR1 anticorps (AA 1-280) | Humain | Souris Monoclonal |
|
595,47 €
Voir le prix
|
|
| DcR1 anticorps (PE) | Souris | Hamster arménien Monoclonal |
|
362,35 €
Voir le prix
|
|
| DcR1 anticorps | Humain, Souris, Rat | Lapin Monoclonal |
|
522,50 €
Voir le prix
|
Primary Antibody
- WB (Western Blotting: Application indiquée)
- IF (cc) (Immunofluorescence (Cultured Cells): Application indiquée)
- IF (p) (Immunofluorescence (Paraffin-embedded Sections): Application indiquée)
- Reactivité
- Humain
- Hôte
- Lapin
- Clonalité
- Polyclonal
- Conjugué
- AbBy Fluor® 680
- Isotype
- IgG
- Epitope
- AA 51-150
Primary Antibody
- WB (Western Blotting: Application indiquée)
- IF (cc) (Immunofluorescence (Cultured Cells): Application indiquée)
- IF (p) (Immunofluorescence (Paraffin-embedded Sections): Application indiquée)
- Reactivité
- Humain
- Hôte
- Lapin
- Clonalité
- Polyclonal
- Conjugué
- AbBy Fluor® 647
- Isotype
- IgG
- Epitope
- AA 51-150
Primary Antibody
- WB (Western Blotting: Application indiquée)
- IF (cc) (Immunofluorescence (Cultured Cells): Application indiquée)
- IF (p) (Immunofluorescence (Paraffin-embedded Sections): Application indiquée)
- Reactivité
- Humain
- Hôte
- Lapin
- Clonalité
- Polyclonal
- Conjugué
- AbBy Fluor® 488
- Isotype
- IgG
- Epitope
- AA 51-150
Primary Antibody
- WB (Western Blotting: Application indiquée)
- IF (cc) (Immunofluorescence (Cultured Cells): Application indiquée)
- IF (p) (Immunofluorescence (Paraffin-embedded Sections): Application indiquée)
- Reactivité
- Humain
- Hôte
- Lapin
- Clonalité
- Polyclonal
- Conjugué
- AbBy Fluor® 555
- Isotype
- IgG
- Epitope
- AA 51-150
Primary Antibody
- WB (Western Blotting: Application indiquée)
- IHC (fro) (Immunohistochemistry (Frozen Sections): Application indiquée)
- IHC (p) (Immunohistochemistry (Paraffin-embedded Sections): Application indiquée)
- Reactivité
- Humain
- Hôte
- Lapin
- Clonalité
- Polyclonal
- Conjugué
- Biotin
- Isotype
- IgG
- Epitope
- AA 51-150
Primary Antibody
- WB (Western Blotting: Application indiquée)
- IF (cc) (Immunofluorescence (Cultured Cells): Application indiquée)
- IF (p) (Immunofluorescence (Paraffin-embedded Sections): Application indiquée)
- Reactivité
- Humain
- Hôte
- Lapin
- Clonalité
- Polyclonal
- Conjugué
- AbBy Fluor® 750
- Isotype
- IgG
- Epitope
- AA 51-150
Primary Antibody
- WB (Western Blotting: Application indiquée)
- IF (cc) (Immunofluorescence (Cultured Cells): Application indiquée)
- IF (p) (Immunofluorescence (Paraffin-embedded Sections): Application indiquée)
- Reactivité
- Humain
- Hôte
- Lapin
- Clonalité
- Polyclonal
- Conjugué
- Cy3
- Isotype
- IgG
- Epitope
- AA 51-150
Primary Antibody
- WB (Western Blotting: Application indiquée)
- IF (cc) (Immunofluorescence (Cultured Cells): Application indiquée)
- IF (p) (Immunofluorescence (Paraffin-embedded Sections): Application indiquée)
- Reactivité
- Humain
- Hôte
- Lapin
- Clonalité
- Polyclonal
- Conjugué
- AbBy Fluor® 594
- Isotype
- IgG
- Epitope
- AA 51-150
Primary Antibody
- WB (Western Blotting: Application indiquée)
- IF (cc) (Immunofluorescence (Cultured Cells): Application indiquée)
- IF (p) (Immunofluorescence (Paraffin-embedded Sections): Application indiquée)
- Reactivité
- Humain
- Hôte
- Lapin
- Clonalité
- Polyclonal
- Conjugué
- Cy5
- Isotype
- IgG
- Epitope
- AA 51-150
Primary Antibody
- WB (Western Blotting: Application indiquée)
- IHC (fro) (Immunohistochemistry (Frozen Sections): Application indiquée)
- IHC (p) (Immunohistochemistry (Paraffin-embedded Sections): Application indiquée)
- Reactivité
- Humain
- Hôte
- Lapin
- Clonalité
- Polyclonal
- Conjugué
- HRP
- Isotype
- IgG
- Epitope
- AA 51-150
Primary Antibody
- WB (Western Blotting: Application indiquée)
- IF (cc) (Immunofluorescence (Cultured Cells): Application indiquée)
- IF (p) (Immunofluorescence (Paraffin-embedded Sections): Application indiquée)
- Reactivité
- Humain
- Hôte
- Lapin
- Clonalité
- Polyclonal
- Conjugué
- Cy5.5
- Isotype
- IgG
- Epitope
- AA 51-150
Primary Antibody
- WB (Western Blotting: Application indiquée)
- IF (cc) (Immunofluorescence (Cultured Cells): Application indiquée)
- IF (p) (Immunofluorescence (Paraffin-embedded Sections): Application indiquée)
- Reactivité
- Humain
- Hôte
- Lapin
- Clonalité
- Polyclonal
- Conjugué
- FITC
- Isotype
- IgG
- Epitope
- AA 51-150
Primary Antibody
- WB (Western Blotting: Application indiquée)
- IF (cc) (Immunofluorescence (Cultured Cells): Application indiquée)
- IF (p) (Immunofluorescence (Paraffin-embedded Sections): Application indiquée)
- Reactivité
- Humain
- Hôte
- Lapin
- Clonalité
- Polyclonal
- Conjugué
- Cy7
- Isotype
- IgG
- Epitope
- AA 51-150
Primary Antibody
- WB (Western Blotting: Application indiquée)
- Reactivité
- Humain
- Hôte
- Souris
- Clonalité
- Polyclonal
- Conjugué
- unconjugated
Primary Antibody
- WB (Western Blotting: Image de validation disponible)
- IF (Immunofluorescence: Image de validation disponible)
- ELISA (ELISA: Application indiquée)
- Reactivité
- Humain, Souris, Rat
- Hôte
- Lapin
- Clonalité
- Polyclonal
- Conjugué
- unconjugated
- Epitope
- 2nd Extracellular Domain
Primary Antibody
- WB (Western Blotting: Image de validation disponible)
- IHC (Immunohistochemistry: Image de validation disponible)
- ICC (Immunocytochemistry: Application indiquée)
- IP (Immunoprecipitation: Application indiquée)
- Reactivité
- Humain
- Hôte
- Lapin
- Clonalité
- Polyclonal
- Conjugué
- unconjugated
- Isotype
- IgG
- Epitope
- AA 32-244
Primary Antibody
- WB (Western Blotting: Image de validation disponible)
- IF (Immunofluorescence: Image de validation disponible)
- EIA (Enzyme Immunoassay: Application indiquée)
- Reactivité
- Humain, Souris, Rat
- Hôte
- Lapin
- Clonalité
- Polyclonal
- Conjugué
- unconjugated
- Isotype
- IgG
Primary Antibody
- FACS (Flow Cytometry: Image de validation disponible)
- Reactivité
- Humain
- Hôte
- Souris
- Clonalité
- Monoclonal
- Conjugué
- unconjugated
- Isotype
- IgG1
- Epitope
- AA 1-280
Primary Antibody
- FACS (Flow Cytometry: Image de validation disponible)
- WB (Western Blotting: Application indiquée)
- Reactivité
- Souris
- Hôte
- Hamster arménien
- Clonalité
- Monoclonal
- Clone
- mDcR1-3
- Conjugué
- PE
- Isotype
- IgG
Primary Antibody
- WB (Western Blotting: Image de validation disponible)
- ICC (Immunocytochemistry: Application indiquée)
- IF (Immunofluorescence: Application indiquée)
- Reactivité
- Humain, Souris, Rat
- Hôte
- Lapin
- Clonalité
- Monoclonal
- Clone
- 31T28
- Conjugué
- unconjugated
- Isotype
- IgG
Dernières publications pour nos DcR1 Anticorps
: "Impact of p53 status on TRAIL-mediated apoptotic and non-apoptotic signaling in cancer cells." dans: PLoS ONE, Vol. 14, Issue 4, pp. e0214847, (2019) (PubMed).
: "Combination therapy with c-met inhibitor and TRAIL enhances apoptosis in dedifferentiated liposarcoma patient-derived cells." dans: BMC cancer, Vol. 19, Issue 1, pp. 496, (2019) (PubMed).
: "TRAIL-Receptor 4 Modulates γδ T Cell-Cytotoxicity Toward Cancer Cells." dans: Frontiers in immunology, Vol. 10, pp. 2044, (2019) (PubMed).
: "Dual role of DR5 in death and survival signaling leads to TRAIL resistance in cancer cells." dans: Cell death & disease, Vol. 8, Issue 8, pp. e3025, (2018) (PubMed).
: "TRAIL regulatory receptors constrain human hepatic stellate cell apoptosis." dans: Scientific reports, Vol. 7, Issue 1, pp. 5514, (2017) (PubMed).
: "Targeting Apoptotic Activity Against Prostate Cancer Stem Cells." dans: International journal of molecular sciences, Vol. 18, Issue 8, (2017) (PubMed).
: "The TRAIL-Induced Cancer Secretome Promotes a Tumor-Supportive Immune Microenvironment via CCR2." dans: Molecular cell, Vol. 65, Issue 4, pp. 730-742.e5, (2017) (PubMed).
: "Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma." dans: Stem cells translational medicine, Vol. 3, Issue 2, pp. 172-82, (2014) (PubMed).
: "Dominant negative effects of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 4 on TRAIL receptor 1 signaling by formation of heteromeric complexes." dans: The Journal of biological chemistry, Vol. 289, Issue 23, pp. 16576-87, (2014) (PubMed).
: "TRAIL-engineered bone marrow-derived mesenchymal stem cells: TRAIL expression and cytotoxic effects on C6 glioma cells." dans: Anticancer research, Vol. 34, Issue 2, pp. 729-34, (2014) (PubMed).
: "Combination therapy with c-met inhibitor and TRAIL enhances apoptosis in dedifferentiated liposarcoma patient-derived cells." dans: BMC cancer, Vol. 19, Issue 1, pp. 496, (2019) (PubMed).
: "TRAIL-Receptor 4 Modulates γδ T Cell-Cytotoxicity Toward Cancer Cells." dans: Frontiers in immunology, Vol. 10, pp. 2044, (2019) (PubMed).
: "Dual role of DR5 in death and survival signaling leads to TRAIL resistance in cancer cells." dans: Cell death & disease, Vol. 8, Issue 8, pp. e3025, (2018) (PubMed).
: "TRAIL regulatory receptors constrain human hepatic stellate cell apoptosis." dans: Scientific reports, Vol. 7, Issue 1, pp. 5514, (2017) (PubMed).
: "Targeting Apoptotic Activity Against Prostate Cancer Stem Cells." dans: International journal of molecular sciences, Vol. 18, Issue 8, (2017) (PubMed).
: "The TRAIL-Induced Cancer Secretome Promotes a Tumor-Supportive Immune Microenvironment via CCR2." dans: Molecular cell, Vol. 65, Issue 4, pp. 730-742.e5, (2017) (PubMed).
: "Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma." dans: Stem cells translational medicine, Vol. 3, Issue 2, pp. 172-82, (2014) (PubMed).
: "Dominant negative effects of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 4 on TRAIL receptor 1 signaling by formation of heteromeric complexes." dans: The Journal of biological chemistry, Vol. 289, Issue 23, pp. 16576-87, (2014) (PubMed).
: "TRAIL-engineered bone marrow-derived mesenchymal stem cells: TRAIL expression and cytotoxic effects on C6 glioma cells." dans: Anticancer research, Vol. 34, Issue 2, pp. 729-34, (2014) (PubMed).
Pseudonymes pour DcR1 Anticorps
TNF receptor superfamily member 10c (TNFRSF10C) AnticorpsCD263 Anticorps
DCR1 Anticorps
DCR1-TNFR Anticorps
LIT Anticorps
TNFRSF10C Anticorps
TRAIL-R3 Anticorps
TRAILR3 Anticorps
TRID Anticorps
Avez-vous cherché autre chose?
- DCPS Anticorps
- DCP2 Anticorps
- DCP1B Anticorps
- DCP1A Anticorps
- DCMP Deaminase Anticorps
- DCLRE1C Anticorps
- DCLRE1B Anticorps
- DCLK3 Anticorps
- DCLK2 Anticorps
- DCLK1 Anticorps
- DCL1 Anticorps
- DCK Anticorps
- DCI Anticorps
- DCHS1 Anticorps
- DCDC5 Anticorps
- DCDC2B Anticorps
- DCDC2 Anticorps
- DCC Anticorps
- DCBLD2 Anticorps
- DCAKD Anticorps
- DcR2 Anticorps
- DCST1 Anticorps
- DCT Anticorps
- DCTN3 Anticorps
- DCTN5 Anticorps
- DCTN6 Anticorps
- DCTPP1 Anticorps
- DCUN1D1 Anticorps
- DCUN1D2 Anticorps
- DCUN1D3 Anticorps
- DCUN1D4 Anticorps
- DCXR Anticorps
- DcyD Anticorps
- DDA1 Anticorps
- DDAH1 Anticorps
- DDAH2 Anticorps
- DDB1 Anticorps
- DDB2 Anticorps
- DDC Anticorps
- DDHD1 Anticorps
Vous êtes ici:
